Phase II trial of menogaril in non-Hodgkin's lymphomas: A southwest oncology group trial

Dennis F. Moore, Thomas D. Brown, Michael LeBlanc, Steve Dahlberg, Thomas P Miller, Suzanne McClure, Richard I. Fisher

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To assess the efficacy and toxicity of menogaril against non-Hodgkin's lymphoma (NHL) in a group of previously treated patients. Patients and methods: Sixty-two eligible patients with a histologic diagnosis of NHL were enrolled, 35 of who had intermediate or high-grade histologies and 27 of who had low-grade lymphomas. Patients with intermediate or high-grade lymphomas had received only 1 prior chemotherapy regimen, while patients with low-grade histologies had received 1 or 2 prior chemotherapy regimens. Menogaril was administered at 160 mg/m2 intravenously over 1 hour, once every 28 days. Results: Among the 35 patients with intermediate or high-grade lymphomas who were evaluable for response, 6 of 35 patients achieved a partial response (PR) for a response rate of 17% (95% confidence interval: 7%-34%). Median survival in this group of patients was 13 months. For those patients with low-grade lymphoma, 5 of 26 patients achieved a PR for a response rate of 19% (95% confidence interval: 6%-38%). No complete responses were observed in either patient group. The incidence of serious (grade 3 or 4) toxicity for those with intermediate/high-grade and low-grade lymphomas was 43% and 44%, respectively. Most of these toxic effects consisted of reversible myelosuppression. Menogaril was discontinued in 2 patients due to prolonged neutropenia. Cardiotoxicity was observed in 4 patients, requiring discontinuation of the drug in 1 patient. No treatment-related deaths occurred and the overall toxicity was felt to be acceptable. Conclusion: The observed antitumor activity of single agent menogaril against both intermediate/high- grade and low-grade lymphomas was modest. Further exploration of this agent in patients with non-Hodgkin's lymphomas does not seem warranted.

Original languageEnglish (US)
Pages (from-to)169-172
Number of pages4
JournalInvestigational New Drugs
Volume17
Issue number2
DOIs
StatePublished - 1999

Fingerprint

Menogaril
Non-Hodgkin's Lymphoma
Histology
Confidence Intervals
Drug Therapy

Keywords

  • Menogaril
  • Non-Hodgkin's lymphoma
  • Southwest Oncology Group

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Moore, D. F., Brown, T. D., LeBlanc, M., Dahlberg, S., Miller, T. P., McClure, S., & Fisher, R. I. (1999). Phase II trial of menogaril in non-Hodgkin's lymphomas: A southwest oncology group trial. Investigational New Drugs, 17(2), 169-172. https://doi.org/10.1023/A:1006375301205

Phase II trial of menogaril in non-Hodgkin's lymphomas : A southwest oncology group trial. / Moore, Dennis F.; Brown, Thomas D.; LeBlanc, Michael; Dahlberg, Steve; Miller, Thomas P; McClure, Suzanne; Fisher, Richard I.

In: Investigational New Drugs, Vol. 17, No. 2, 1999, p. 169-172.

Research output: Contribution to journalArticle

Moore, DF, Brown, TD, LeBlanc, M, Dahlberg, S, Miller, TP, McClure, S & Fisher, RI 1999, 'Phase II trial of menogaril in non-Hodgkin's lymphomas: A southwest oncology group trial', Investigational New Drugs, vol. 17, no. 2, pp. 169-172. https://doi.org/10.1023/A:1006375301205
Moore, Dennis F. ; Brown, Thomas D. ; LeBlanc, Michael ; Dahlberg, Steve ; Miller, Thomas P ; McClure, Suzanne ; Fisher, Richard I. / Phase II trial of menogaril in non-Hodgkin's lymphomas : A southwest oncology group trial. In: Investigational New Drugs. 1999 ; Vol. 17, No. 2. pp. 169-172.
@article{75c3e2e2455b4e35a1a1377f92391a2e,
title = "Phase II trial of menogaril in non-Hodgkin's lymphomas: A southwest oncology group trial",
abstract = "Purpose: To assess the efficacy and toxicity of menogaril against non-Hodgkin's lymphoma (NHL) in a group of previously treated patients. Patients and methods: Sixty-two eligible patients with a histologic diagnosis of NHL were enrolled, 35 of who had intermediate or high-grade histologies and 27 of who had low-grade lymphomas. Patients with intermediate or high-grade lymphomas had received only 1 prior chemotherapy regimen, while patients with low-grade histologies had received 1 or 2 prior chemotherapy regimens. Menogaril was administered at 160 mg/m2 intravenously over 1 hour, once every 28 days. Results: Among the 35 patients with intermediate or high-grade lymphomas who were evaluable for response, 6 of 35 patients achieved a partial response (PR) for a response rate of 17{\%} (95{\%} confidence interval: 7{\%}-34{\%}). Median survival in this group of patients was 13 months. For those patients with low-grade lymphoma, 5 of 26 patients achieved a PR for a response rate of 19{\%} (95{\%} confidence interval: 6{\%}-38{\%}). No complete responses were observed in either patient group. The incidence of serious (grade 3 or 4) toxicity for those with intermediate/high-grade and low-grade lymphomas was 43{\%} and 44{\%}, respectively. Most of these toxic effects consisted of reversible myelosuppression. Menogaril was discontinued in 2 patients due to prolonged neutropenia. Cardiotoxicity was observed in 4 patients, requiring discontinuation of the drug in 1 patient. No treatment-related deaths occurred and the overall toxicity was felt to be acceptable. Conclusion: The observed antitumor activity of single agent menogaril against both intermediate/high- grade and low-grade lymphomas was modest. Further exploration of this agent in patients with non-Hodgkin's lymphomas does not seem warranted.",
keywords = "Menogaril, Non-Hodgkin's lymphoma, Southwest Oncology Group",
author = "Moore, {Dennis F.} and Brown, {Thomas D.} and Michael LeBlanc and Steve Dahlberg and Miller, {Thomas P} and Suzanne McClure and Fisher, {Richard I.}",
year = "1999",
doi = "10.1023/A:1006375301205",
language = "English (US)",
volume = "17",
pages = "169--172",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Phase II trial of menogaril in non-Hodgkin's lymphomas

T2 - A southwest oncology group trial

AU - Moore, Dennis F.

AU - Brown, Thomas D.

AU - LeBlanc, Michael

AU - Dahlberg, Steve

AU - Miller, Thomas P

AU - McClure, Suzanne

AU - Fisher, Richard I.

PY - 1999

Y1 - 1999

N2 - Purpose: To assess the efficacy and toxicity of menogaril against non-Hodgkin's lymphoma (NHL) in a group of previously treated patients. Patients and methods: Sixty-two eligible patients with a histologic diagnosis of NHL were enrolled, 35 of who had intermediate or high-grade histologies and 27 of who had low-grade lymphomas. Patients with intermediate or high-grade lymphomas had received only 1 prior chemotherapy regimen, while patients with low-grade histologies had received 1 or 2 prior chemotherapy regimens. Menogaril was administered at 160 mg/m2 intravenously over 1 hour, once every 28 days. Results: Among the 35 patients with intermediate or high-grade lymphomas who were evaluable for response, 6 of 35 patients achieved a partial response (PR) for a response rate of 17% (95% confidence interval: 7%-34%). Median survival in this group of patients was 13 months. For those patients with low-grade lymphoma, 5 of 26 patients achieved a PR for a response rate of 19% (95% confidence interval: 6%-38%). No complete responses were observed in either patient group. The incidence of serious (grade 3 or 4) toxicity for those with intermediate/high-grade and low-grade lymphomas was 43% and 44%, respectively. Most of these toxic effects consisted of reversible myelosuppression. Menogaril was discontinued in 2 patients due to prolonged neutropenia. Cardiotoxicity was observed in 4 patients, requiring discontinuation of the drug in 1 patient. No treatment-related deaths occurred and the overall toxicity was felt to be acceptable. Conclusion: The observed antitumor activity of single agent menogaril against both intermediate/high- grade and low-grade lymphomas was modest. Further exploration of this agent in patients with non-Hodgkin's lymphomas does not seem warranted.

AB - Purpose: To assess the efficacy and toxicity of menogaril against non-Hodgkin's lymphoma (NHL) in a group of previously treated patients. Patients and methods: Sixty-two eligible patients with a histologic diagnosis of NHL were enrolled, 35 of who had intermediate or high-grade histologies and 27 of who had low-grade lymphomas. Patients with intermediate or high-grade lymphomas had received only 1 prior chemotherapy regimen, while patients with low-grade histologies had received 1 or 2 prior chemotherapy regimens. Menogaril was administered at 160 mg/m2 intravenously over 1 hour, once every 28 days. Results: Among the 35 patients with intermediate or high-grade lymphomas who were evaluable for response, 6 of 35 patients achieved a partial response (PR) for a response rate of 17% (95% confidence interval: 7%-34%). Median survival in this group of patients was 13 months. For those patients with low-grade lymphoma, 5 of 26 patients achieved a PR for a response rate of 19% (95% confidence interval: 6%-38%). No complete responses were observed in either patient group. The incidence of serious (grade 3 or 4) toxicity for those with intermediate/high-grade and low-grade lymphomas was 43% and 44%, respectively. Most of these toxic effects consisted of reversible myelosuppression. Menogaril was discontinued in 2 patients due to prolonged neutropenia. Cardiotoxicity was observed in 4 patients, requiring discontinuation of the drug in 1 patient. No treatment-related deaths occurred and the overall toxicity was felt to be acceptable. Conclusion: The observed antitumor activity of single agent menogaril against both intermediate/high- grade and low-grade lymphomas was modest. Further exploration of this agent in patients with non-Hodgkin's lymphomas does not seem warranted.

KW - Menogaril

KW - Non-Hodgkin's lymphoma

KW - Southwest Oncology Group

UR - http://www.scopus.com/inward/record.url?scp=0345440008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345440008&partnerID=8YFLogxK

U2 - 10.1023/A:1006375301205

DO - 10.1023/A:1006375301205

M3 - Article

C2 - 10638487

AN - SCOPUS:0345440008

VL - 17

SP - 169

EP - 172

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -